Immunomodulators, Biologics, and 5-ASA for Inflammatory Bowel Disease and Major Adverse Cardiovascular Events in Older Adults

Is type of inflammatory bowel disease (IBD) treatment associated with risk of major adverse cardiovascular events (MACE) in Medicare patients with IBD?In this comparative effectiveness study of 16 387 Medicare beneficiaries with IBD, there were no statistically significant differences in MACE events over up to 3 years of follow-up between patients treated with immunomodulators or biologics vs those treated with 5-aminosalicylic acid (5-ASA).This comparative effectiveness study found that use of immunomodulators or biologics was not associated with increased risk of MACE in older adults with IBD compared with 5-ASA therapy.

Corresponding Author: Tianze Jiao, PhD, Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, 1889 Museum Rd, Room 6301, Gainesville, FL 32611 (tianzejiao@ufl.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.